YUTREPIA

Liquidia, the pharmaceutical company behind the pulmonary hypertension therapy YUTREPIA, is the subject of valuation analysis suggesting its shares could trade roughly 74% below fair value. The discussion comes as a recent court ruling creates uncertainty over patient access to YUTREPIA, weighing on the stock despite what analysts see as strong underlying value in the drug.